Valeant Pharmaceuticals Intl Stock Price, News & Analysis (TSE:VRX)

C$23.65 +0.51 (+2.20 %)
(As of 02/23/2018 04:00 PM ET)
Previous CloseC$23.65
Today's RangeC$23.12 - C$23.90
52-Week RangeC$11.20 - C$30.56
Volume797,600 shs
Average Volume1.81 million shs
Market CapitalizationC$8.24 billion
P/E Ratio4.77
Dividend YieldN/A
Beta-0.89

About Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio4.76814516129032
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC$4.96
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%

Miscellaneous

EmployeesN/A
Outstanding Shares348,592,000

Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

When will Valeant Pharmaceuticals Intl make its next earnings announcement?

Valeant Pharmaceuticals Intl is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Valeant Pharmaceuticals Intl.

Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2018?

4 analysts have issued twelve-month price objectives for Valeant Pharmaceuticals Intl's shares. Their predictions range from C$19.00 to C$25.50. On average, they anticipate Valeant Pharmaceuticals Intl's share price to reach C$22.50 in the next twelve months. View Analyst Ratings for Valeant Pharmaceuticals Intl.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer (Age 61)
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President (Age 61)
  • Christina Ackermann, Executive Vice President, General Counsel (Age 52)
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International (Age 55)
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology (Age 50)
  • Thomas W. Ross Sr, Lead Independent Director (Age 66)
  • Richard U. DeSchutter, Independent Director (Age 76)
  • Fredric N. Eshelman Ph.D., Independent Director (Age 68)
  • D. Robert Hale, Independent Director (Age 32)
  • Argeris N. Karabelas Ph.D., Independent Director (Age 64)

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately C$23.65.

How big of a company is Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl has a market capitalization of C$8.24 billion.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals Intl (TSE:VRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.402.20
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$22.50C$22.50C$22.50C$23.33
Price Target Upside: 18.86% upside18.86% upside18.86% upside8.78% upside

Valeant Pharmaceuticals Intl (TSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl (TSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00View Rating Details
11/8/2017TD SecuritiesUpgradeHold -> BuyC$25.50View Rating Details
6/29/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Valeant Pharmaceuticals Intl (TSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl (TSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018C$1.23N/AView Earnings Details
11/7/2017Q3 2017C$1.13C$1.30C$2.74 billionC$2.78 billionViewN/AView Earnings Details
8/8/2017Q2 2017C$1.28C$1.41C$2.94 billionC$3.00 billionViewN/AView Earnings Details
5/9/2017Q1 2017C$3.71C$2.79 billionViewN/AView Earnings Details
2/28/2017Q4 2016C$1.68C$3.21 billionViewN/AView Earnings Details
11/8/2016Q3 2016C$2.02C$3.23 billionViewN/AView Earnings Details
8/9/2016Q2 2016C$1.81C$3.82 billionC$3.12 billionViewN/AView Earnings Details
6/7/2016Q1 2016C$2.04C$1.74C$3.14 billionC$3.26 billionViewN/AView Earnings Details
3/15/2016Q4 2015C$3.24C$3.60 billionViewN/AView Earnings Details
10/19/2015Q3 2015C$3.50C$3.62C$3.62 billionC$3.74 billionViewN/AView Earnings Details
7/23/2015Q2 2015C$3.09C$3.17C$3.36 billionViewN/AView Earnings Details
4/29/2015Q1 2015C$2.82C$2.64 billionViewN/AView Earnings Details
2/22/2015Q4 2014C$3.30C$2.86 billionViewN/AView Earnings Details
10/20/2014Q3 2014C$2.20C$2.32 billionViewN/AView Earnings Details
7/31/2014Q2 2014C$1.98C$2.10 billionViewN/AView Earnings Details
5/8/2014C$1.83C$1.90C$2.05 billionViewN/AView Earnings Details
2/27/2014Q4 2013C$2.18C$2.39C$2.29 billionViewN/AView Earnings Details
10/31/2013Q3 2013C$1.47C$1.47C$1.71 billionC$1.61 billionViewN/AView Earnings Details
8/7/20132Q13C$0.03C$1.15 billionC$1.14 billionViewN/AView Earnings Details
5/2/2013Q1 2013C$1.28C$1.31C$1.10 billionC$1.08 billionViewN/AView Earnings Details
2/28/2013Q4 2012C$1.24C$1.23ViewN/AView Earnings Details
11/2/2012Q3 2012C$1.11C$1.11ViewN/AView Earnings Details
8/2/2012Q2 2012C$1.00C$1.02ViewN/AView Earnings Details
5/3/2012Q1 2012C$0.88C$1.12ViewN/AView Earnings Details
2/27/2012Q4 2011C$0.85C$0.90ViewN/AView Earnings Details
11/3/2011Q3 2011C$0.56C$0.63ViewN/AView Earnings Details
8/4/2011Q2 2011C$0.66ViewN/AView Earnings Details
5/9/2011Q1 2011C$0.51C$0.47ViewN/AView Earnings Details
2/24/2011Q4 2010C$0.49ViewN/AView Earnings Details
11/4/2010Q3 2010C$0.31C($0.28)ViewN/AView Earnings Details
8/5/2010Q2 2010C$0.35ViewN/AView Earnings Details
5/6/2010Q1 2010C$0.27C$0.55ViewN/AView Earnings Details
8/6/2009Q2 2009C$0.40C$0.37ViewN/AView Earnings Details
5/8/2009Q1 2009C$2.18C$0.32ViewN/AView Earnings Details
2/26/2009Q4 2008C$0.39C$0.42ViewN/AView Earnings Details
11/6/2008Q3 2008C$0.26C$0.37ViewN/AView Earnings Details
5/8/2008Q1 2008C$0.38C$0.43ViewN/AView Earnings Details
3/13/2008Q4 2007C$0.40C$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Valeant Pharmaceuticals Intl (TSE:VRX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Valeant Pharmaceuticals Intl (TSE:VRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Valeant Pharmaceuticals Intl (TSE VRX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl (TSE VRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2017Schutter Richard Urbain DeDirectorBuy10,000C$14.33C$143,300.00
8/21/2017Schutter Richard Urbain DeDirectorBuy4,900C$14.35C$70,315.00
8/9/2017John PaulsonDirectorSell24,700C$14.66C$362,102.00
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals Intl (TSE VRX) News Headlines

Source:
DateHeadline
Is Valeant Pharmaceuticals International, Inc. a Buy?Is Valeant Pharmaceuticals International, Inc. a Buy?
finance.yahoo.com - February 23 at 5:55 PM
Why Valeant is growing its Raleigh teamWhy Valeant is growing its Raleigh team
finance.yahoo.com - February 21 at 5:25 PM
Valeant Pharmaceuticals Intl (VRX) to Release Earnings on WednesdayValeant Pharmaceuticals Intl (VRX) to Release Earnings on Wednesday
www.americanbankingnews.com - February 21 at 4:12 AM
VRX Crosses Above Average Analyst TargetVRX Crosses Above Average Analyst Target
www.nasdaq.com - February 16 at 5:16 PM
Francis Chou Nearly Dumps Entire Stake in Valeant, Teva and Overstock in 4th QuarterFrancis Chou Nearly Dumps Entire Stake in Valeant, Teva and Overstock in 4th Quarter
finance.yahoo.com - February 16 at 5:16 PM
Valeant Pharmaceuticals Intl Inc.: Get Ready for a Massive OpportunityValeant Pharmaceuticals Intl Inc.: Get Ready for a Massive Opportunity
www.fool.ca - February 14 at 4:25 PM
Valeant Pharma (VRX) Unit, Ortho Dermatologics, Granted FDA Acceptance for JEMDEL Plaque Psoriasis TreatmentValeant Pharma (VRX) Unit, Ortho Dermatologics, Granted FDA Acceptance for JEMDEL Plaque Psoriasis Treatment
www.streetinsider.com - February 14 at 9:51 AM
Good news for Super Bowl viewing — no more ads for toenail-fungus drugsGood news for Super Bowl viewing — no more ads for toenail-fungus drugs
finance.yahoo.com - February 2 at 9:42 AM
Noteworthy ETF Outflows: PPH, TEVA, VRX, MYL - NasdaqNoteworthy ETF Outflows: PPH, TEVA, VRX, MYL - Nasdaq
www.nasdaq.com - January 24 at 8:08 AM
Why The Future Of Valeant Looks Bright - Seeking AlphaWhy The Future Of Valeant Looks Bright - Seeking Alpha
seekingalpha.com - January 24 at 8:08 AM
Stocks making the biggest moves premarket: CMCSA, GE, UTX, SWK, UAL, WFC & moreStocks making the biggest moves premarket: CMCSA, GE, UTX, SWK, UAL, WFC & more
finance.yahoo.com - January 24 at 8:08 AM
Glenn Greenberg: A Successful Hedge Fund ManagerGlenn Greenberg: A Successful Hedge Fund Manager
finance.yahoo.com - January 23 at 5:24 PM
Some Branded Drugs Going Generic In 2018 - NasdaqSome Branded Drugs Going Generic In 2018 - Nasdaq
www.nasdaq.com - January 22 at 5:28 AM
Valeant: What Does Papas New Promise Mean For The Company? - Seeking AlphaValeant: What Does Papa's New Promise Mean For The Company? - Seeking Alpha
seekingalpha.com - January 12 at 4:17 PM
Behind Valeant’s Branded Drugs: Other 3Q17 PerformancesBehind Valeant’s Branded Drugs: Other 3Q17 Performances
finance.yahoo.com - January 8 at 10:43 AM
How Did Bausch + Lomb’s Top Products Perform in 3Q17?How Did Bausch + Lomb’s Top Products Perform in 3Q17?
finance.yahoo.com - January 5 at 10:45 AM
3 Compelling Reasons Valeant Pharmaceuticals Exploded Higher by 24% in December3 Compelling Reasons Valeant Pharmaceuticals Exploded Higher by 24% in December
finance.yahoo.com - January 5 at 10:45 AM
Valeant Pharma (VRX) Pays Down Additional $300M in Senior Secured Term Loans; Reduced Debt by More than $6.5B Since Q116Valeant Pharma (VRX) Pays Down Additional $300M in Senior Secured Term Loans; Reduced Debt by More than $6.5B Since Q116
www.streetinsider.com - January 3 at 4:27 PM
Valeant (VRX) to Settle Allergan Litigation for $290 Million - NasdaqValeant (VRX) to Settle Allergan Litigation for $290 Million - Nasdaq
www.nasdaq.com - January 3 at 9:46 AM
Valeant shares rise after company pays down additional $300 mln in debtValeant shares rise after company pays down additional $300 mln in debt
finance.yahoo.com - January 3 at 9:46 AM
Valeant Pays Down $300 Million Of Senior Secured Term LoansValeant Pays Down $300 Million Of Senior Secured Term Loans
finance.yahoo.com - January 3 at 9:46 AM
Patents, Trump, Viagra: My Good and Bad Calls of 2017Patents, Trump, Viagra: My Good and Bad Calls of 2017
finance.yahoo.com - January 3 at 9:46 AM
Valeant Pharmaceuticals International (VRX) a Buy on Solid Earnings Visibility - Investorplace.comValeant Pharmaceuticals International (VRX) a Buy on Solid Earnings Visibility - Investorplace.com
investorplace.com - January 2 at 10:10 PM
Citi Told Some Customers to Buy the SellsCiti Told Some Customers to Buy the Sells
finance.yahoo.com - January 2 at 10:22 AM
Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for Valeant Pharmaceuticals International, Inc. (VRX)Cantor Fitzgerald Research Analysts Decrease Earnings Estimates for Valeant Pharmaceuticals International, Inc. (VRX)
www.americanbankingnews.com - December 30 at 7:04 PM
Pershing Square, Valeant Agree To Pay $290 Mln To Settle Allergan LawsuitPershing Square, Valeant Agree To Pay $290 Mln To Settle Allergan Lawsuit
www.nasdaq.com - December 30 at 10:13 AM
Kessler Topaz Represents Investors in $290 Million Total Settlement Recovery Reached with Valeant Pharmaceuticals and Bill Ackmans Pershing Square Over Insider Trading ClaimsKessler Topaz Represents Investors in $290 Million Total Settlement Recovery Reached with Valeant Pharmaceuticals and Bill Ackman's Pershing Square Over Insider Trading Claims
www.prnewswire.com - December 29 at 7:52 PM
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio - NasdaqMallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio - Nasdaq
www.nasdaq.com - December 27 at 1:11 PM
Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose ... - PR Newswire (press release)Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose ... - PR Newswire (press release)
www.prnewswire.com - December 23 at 4:33 AM
Valeant Pharma (VRX) Subsidiary Bausch and Lomb Granted FDA Approval of LUMIFY - StreetInsider.comValeant Pharma (VRX) Subsidiary Bausch and Lomb Granted FDA Approval of LUMIFY - StreetInsider.com
www.streetinsider.com - December 22 at 11:32 PM
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals - PR Newswire (press release)Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals - PR Newswire (press release)
www.prnewswire.com - December 21 at 10:32 AM
Valeant: Bear Raises Price Target 20% While Shorts Flee - Seeking AlphaValeant: Bear Raises Price Target 20% While Shorts Flee - Seeking Alpha
seekingalpha.com - December 21 at 10:32 AM
Valeant: I Was Serious - The Clock Is Ticking - Seeking AlphaValeant: I Was Serious - The Clock Is Ticking - Seeking Alpha
seekingalpha.com - December 19 at 10:34 AM
Valeant Pharmaceuticals Well on the Road to Recovery After Bausch + Lomb Distribution DealValeant Pharmaceuticals Well on the Road to Recovery After Bausch + Lomb Distribution Deal
247wallst.com - December 18 at 4:23 PM
Valeant: Perfect Time For An Equity Raise? - Seeking AlphaValeant: Perfect Time For An Equity Raise? - Seeking Alpha
seekingalpha.com - December 18 at 10:59 AM
CANADA STOCKS-TSX up in broad rally; banks, energy stocks, Valeant leadCANADA STOCKS-TSX up in broad rally; banks, energy stocks, Valeant lead
finance.yahoo.com - December 18 at 10:59 AM
Valeants stock drops after JP Morgan turns bearish - MarketWatchValeant's stock drops after JP Morgan turns bearish - MarketWatch
www.marketwatch.com - December 15 at 4:38 PM
Valeant Pharmaceuticals Intl Inc (VRX) Has a New Bear in TownValeant Pharmaceuticals Intl Inc (VRX) Has a New Bear in Town
finance.yahoo.com - December 14 at 4:55 PM
Pre-Market Most Active for Dec 14, 2017 : TEVA, DIS, VALE, SBGL, VRX, PIR - NasdaqPre-Market Most Active for Dec 14, 2017 : TEVA, DIS, VALE, SBGL, VRX, PIR - Nasdaq
www.nasdaq.com - December 14 at 10:42 AM
Valeant: Im Not Selling A Share - Seeking AlphaValeant: I'm Not Selling A Share - Seeking Alpha
seekingalpha.com - December 14 at 10:42 AM
CANADA STOCKS-TSX advances, lifted by Valeant, financial servicesCANADA STOCKS-TSX advances, lifted by Valeant, financial services
finance.yahoo.com - December 12 at 11:00 AM
Drug industry group sues to stop California drug price lawDrug industry group sues to stop California drug price law
finance.yahoo.com - December 9 at 10:31 AM
Vetr Upgrades Valeant After Price DipsVetr Upgrades Valeant After Price Dips
finance.yahoo.com - December 8 at 10:39 AM
Valeant: What Debt Problem? - Seeking AlphaValeant: What Debt Problem? - Seeking Alpha
seekingalpha.com - December 7 at 4:39 PM
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in NovemberThe Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
finance.yahoo.com - December 6 at 10:49 AM
Investing Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko HealthInvesting Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko Health
finance.yahoo.com - December 5 at 12:16 PM
Valeant Announces Launch Of Private Offering Of Senior NotesValeant Announces Launch Of Private Offering Of Senior Notes
finance.yahoo.com - December 4 at 10:33 AM
Valeant Pharma (VRX), Subsidiary Commence Cash Tender Offers For Up to $1B Outstanding Principal AmountValeant Pharma (VRX), Subsidiary Commence Cash Tender Offers For Up to $1B Outstanding Principal Amount
www.streetinsider.com - December 4 at 10:33 AM
Valeant Pharmaceuticals Intl Inc.: If You’d Bought the Dip, You’re upValeant Pharmaceuticals Intl Inc.: If You’d Bought the Dip, You’re up
www.fool.ca - November 30 at 11:13 AM
Quant Billionaire David Shaw Beats the Drum for Valeant Pharmaceuticals International, Inc. (VRX) and MannKind Corporation (MNKD)Quant Billionaire David Shaw Beats the Drum for Valeant Pharmaceuticals International, Inc. (VRX) and MannKind Corporation (MNKD)
finance.yahoo.com - November 27 at 3:36 PM

SEC Filings

Valeant Pharmaceuticals Intl (TSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Valeant Pharmaceuticals Intl (TSE VRX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.